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ABSTRACT 
Objective: To study the effect of brassinosteroid keto isoform homocastasterone, in diabetic male wistar rat as an antihyperglycemic factor and to 
evaluate its effects on the hemodynamic parameters in rat blood.  
Methods: Diabetes was induced in a group (n=6) of rats with a single peritoneal injection of streptozotocin at 60 mg/kg. bw. With a treatment 
schedule of 15 consecutive days, control (n=6) and diabetic rats received 666µg/kg bw, of homocastasterone. Circulating blood glucose, cell count, 
cell indices, and MDA level was assessed.  
Results: Significant reduction (p<0.05) in blood glucose level and increase in RBCs, WBCs, granulocytes, lymphocytes, monocytes and platelets 
count(p<0.05) along with improved functional indices for HCT, PCV, MCV, MCH, MCHC, MPV, PDW, PCT in homocastasterone treated diabetic group 
was noted. A significant reduction in RBC-MDA level (p<0.001) in the treated group was noted.  
Conclusion: It is suggested that brassinosteroid keto isoform homocastasterone exhibits antiglycemic effect in diabetic rat, and improves RBC, 
WBC, Platelet counts, haemoglobin level, and cell indices, while reducing per oxidative cell damage in RBCs. 
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INTRODUCTION 
Plant growth regulators (PGRs) abscissic acid, indole acidic acid 
(IAA), gibberrellic acid (GA3), jasmonic acid and brassinosteroids 
(BS) are facilitate growth, flowering, seedling and immune 
responses in plants. Brassinosteroids also show significant effect on 
insect egg laying capacity, insect growth regulation, mosquito larval 
growth, fecundity, viability and longevity. Structurally, they are 
similar to mammalian steroids and oxycholesterol. These 
compounds elicit biological response inhuman and animals when 
exposed through diet and herbal folk medicine [1, 2]. Specific 
biological effect of plant BS on mammalian system is not fully 
understood. Studies by Muthuraman et al.[4] and Nirmal kumar et al. 
[5] recognized that 28-homobrassinolide, as an aldo isoform yielded 
antiglycemic effect and increased RBC, WBC, lymphocyte, monocyte, 
granulocyte and haemoglobin (Hb) level in male adult wistar rat. 
PGRs such as indole acidic acid (IAA) had no significant effect on 
haematological parameters while gibberrellic acid (GA3) caused the 
significant increase in RBC and Hb level, in a dose dependent 
manner Muthu et al. [3-7]. 
Diabetic anaemia due to non-enzymatic glycation of RBCs and oxy-
free radical induced cell membrane damages results in decreased 
RBC count and Hb level in Diabetes Mellitus (DM). Abnormal platelet 
count and seen in DM result in the formation of thrombotic plugin 
the blood vessels causing vascular defect. In recent years, attention 
is sought in improving the platelet indices for the treatment of DM in 
addition to improving the RBC and Hb level [7, 8].  As blood is a 
connective tissue comprised of a number of formed elements such as 
RBC, WBC, and platelets, it has a significant role in maintaining 
homeostasis. Factors that modulated their circulating levels were 
considered as holding promise to act as potential therapeutic agents 
or drug candidates.  
In this study the keto phyto steroid homocastasterone (HC) was 
therefore used to investigate its antihyperglycemic effect on normal 
and diabetic rat[9, 10], on their blood elements, and on platelet indices 
(mean platelet volume, platelet distribution width, and platelet–large 
cell ratio) considered as major determinants of atherosclerosis. 
MATERIALS AND METHODS 
Chemical and experimental rat 
All chemicals used in the study were of analytical grade purchased from 
Sigma Aldrich USA, Homocastasterone was courtesy of  Dr. V. S. Pori. 
NCL,  Pune, India. Experimental male wistar albino rats (8-10 wks) were 
purchased from Sri Ragavendra Enterprises, Bengaluru, India. 
Experimental design 
A group of 24rats (150-200 gm) was used for the study. Animal use 
and care were in compliance of the CPCSEA regulations and 
Institutional Animal Ethics Committee (IAEC) guidelines, 
(IAEC/Approval No. 2013-14/01). Rats were divided into four 
groups of 6 animals each, Group I: Normal rat control, Group II: 
Normal rat treated with HC. Group III: Diabetic rat control and 
Group IV: Diabetic rat treated with HC. Diabetes was induced in the 
experimental animals by use of a single intraperitoneal injection of 
60 mg/kg bw streptozotocin in citrate buffer (0.1 M, pH 4.5), 
overnight fasted experimental rats. 48 hrs later, circulating blood 
glucose level in the animals was measured using a glucometer (One 
Touch Horizon, Accuva check). Rats exhibiting blood glucose 
content>250 mg/dl were considered diabetic for use in the 
experiment. Control groups I and III received 50% ethanol alone. 
Groups II and IV were administered 666 mg/kg bw HC in 50% 
ethanol by oral gavage for 15 consecutive days.  
Blood glucose analysis 
Glucose level in circulating rat blood was measured with a 
glucometer (One Touch Horizon, Auccva check) at 5 day interval. 
Blood cell count 
Rat blood cell count was determined every fifth day. RBC, WBC, 
granulocytes, monocytes, lymphocytes, platelets, HCT, PCV, MCV, 
MCHC and MPV, PWD, and PCT were analysed by fully automated 
blood cell counter (RC-210 Fully Automatic Blood Cell Counter, 
Rohan Consortium Pvt. Ltd). Hb level was also determined by the 
same instrument. 
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Lipid peroxidation assay 
Heparinised blood was centrifuged at 3000 rpm in a refrigerated 
table top eppendorf centrifuge for 15 min to remove plasma and the 
buffy coat. The sedimented RBC was washed with physiological 
saline and re-centrifuged at 3000 rpm, three consecutive times, for 
15 min each. Packed RBCs was then collected and stored at-20oC 
until further use. Malondialdehyde (MDA) level of RBC was 
measured by the method of okhava et al.[10]. 
Statistical analysis 
Results of the investigations were expressed as mean±SD, and the 
data were analysed by one way ANOVA employing SPSS software 
16.0 versions. Value of p<0.05 was considered significant. 
RESULTS AND DISCUSSION 
Effect on blood glucose 
The effect of homocastasterone on blood glucose level was assessed 
every 5 days from day one of treatment (table 1). HC treated diabetic 
rat blood glucose level reduced 45% on day 5, 50% on day 10and 
55% on day 15, compared to the diabetic control (p<0.05). 
Effect on RBC count and haemoglobin level 
RBC and Hb level increased significantly in HC treated diabetic group 
compared to diabetic control. RBC count increased 5.2% by day 5, 
21.25% by day 10, and 5.6% by day 15, respectively. RBC count of 
HC treated normal rat only 2.5% by day 5 and 2% by day 15. Hb 
level was 4.76%, 0.16%, and 5.66% on days 5, 10and 15 of diabetic 
treated rat when compared to that of diabetic control. 
Effect on the RBC indices 
Values of RBCs indices, haematocrit (HCT), mean corpuscular volume 
(MCV), mean corpuscular haemoglobin concentration (MCHC), and 
mean corpuscular haemoglobin (MCH) are as presented (table 4). A 
decrease in the indices was noted in HC treated rat blood compared to 
the respective control. HCT and MCV levels decreased significantly in 
diabetic treated group by 5th and 10th
Group 
 day. MCH and MCHC levels also 
decreased significantly in the diabetic treated. 
 
Table 1: Effect of homocastasterone on blood glucose level 
0 Day glucose mg/dl 5 Day glucose mg/dl 10 Day glucose mg/dl 15 Day glucose mg/dl 
Control 103.0±6 110.0±5 105.0±2 92.0±3 
Control+HC 106.0±4 97.0±6 96.0±4# 88.0±2# 
Diabetic control 
# 
280.0±7 300.0±8 300.0±8 315.0±6 
Diabetic+HC 282.0±6 206.0±3* 187.0±7* 172.0±4* 
Values are expressed±SD. Group n = 6, #
Group 
 
Indicates statistical significance against normal control (p<0.05), *Indicates statistical significance against diabetic control (p<0.05).  
 
Table 2: Effect of homocastasterone on RBC, Hb, WBC and platelet count 
RBC 10×6/µl Hb g/µl TWBC10×3/µl  Platelets 10×3/µl 
5 Day 10 Day  15 Day 5 Day 10 Day 15 Day 5 Day 10 Day 15 Day  5 Day  10 Day  15 Day 
Control 7.17±1.02 7.65±1.02 7.83±1.02 14.7±1.08 16.3±0.73 15.9±0.85  25.4±0.86 36.3±0.86 11.5±0.86 424±12 444±12 334±12 




7.97±0.84 5.69±0.84 6.42±0.84 16.0±1.08 13.7±0.73 12.6±0.85* 16.4±0.26 20.8±0.26 3.5±0.26 268±9 164±9 179±9 
Diabetic+HC 8.39±0.72 6.90±0.72 6.78±0.72* 16.6±1.08 14.4±0.73 14.9±0.85* 13.1±0.37* 26.5±0.37* 4.9±0.37* 298±14* 226±14* 266±14* 
Values are expressed±SD. Group n = 6, #
Group  
Indicates statistical significance against normal control (p<0.05), *Indicates statistical significance against diabetic control (p<0.05).  
 
Table 3: Effect of homocastasterone on lymphocyte, monocyte and granulocyte count 
Lymphocytes 10×3/µl Monocytes 10×3/µl Granulocytes 10×3/µl 
5 Day 10 Day 15 Day 5 Day 10 Day 15Day 5 Day 10 Day 15 Day 
Control 20.1±0.5  30.1±0.5  10.6±0.5  2.3±0.07   2.5±0.07 0.4±0.07   3.0±0.03  2.7±0.03   0.6±0.03  
Control+HC 14.8±0.52  19.6±0.52  8.6±0.52  0.4±0.02  1.1±0.02  0.2±0.02   0.4±0.04  1.7±0.04   0.6±0.04  
Diabetic control 16.8±0.23  18.7±0.23  3.2±0.23  1.3±0.02  0.9±0.02  0.1±0.02  0.4±0.03 1.2±0.03 0.2±0.03 
Diabetic+HC 12.3±0.28  23.0±0.28*  4.1±0.28*  0.4±0.02  1.3±0.02 0.1±0.02  0.7±0.04* 2.2±0.04* 0.7±0.04* 
Values are expressed±SD. Group n = 6, #
 
Effect on WBCs count 
A 45 % reduction of total WBC count was noted for normal HC 
treated group compared to control. Diabetic the WBC count was 
27.4% on day 10 and 33.33% on day 15 in HC treated rat showing a 
significant increase compared to the diabetic control. 
Effect on WBC differential count 
A significant reduction in lymphocyte, monocyte, and granulocyte 
counts was noted in normal HC treated rat. In the diabetic treated 
group, the differential count showed significant elevation compared 
to diabetic control (p<0.05). Lymphocytes increased 22.99% and 
28.12% on only 10
Indicates statistical significance against normal control (p<0.05), *Indicates statistical significance against diabetic control (p<0.05).  
th and on 15th day. Monocyte count elevated by 
44.44% at day 10. No significant change in this cell count was 
observed on 5th and 15th day of treatment. Granulocyte count 
reduced 75 to 83.3%, through 5th to 15th
In HC treated normal rat, platelet count reduced 13.67% on day 5
 day of treatment.  
Effect on platelets 
th 
(table 2) when compared to normal, 32.93% on day 10, and 
51.19%by day 15. In HC treated diabetic group, the platelet count 
increased 18.29% on day 5th, 37.80% on day 10th, and 48.60% on 
day 15th 
The control blood glucose estimate in the male wistar rats employed for 
the study was 5.11-6.11 mmol/dl, and falls within the range of 4-10 
mmol/dl reported in literature[
(p<0.05) compared to diabetic control. 
Effect on platelet indices 
MPV, PDW and PCT values decreased in HC treated groups 
compared to control (p<0.05). Diabetic control group showed 
abnormal platelet indices compared to normal control. 
Effect on the lipid peroxidation 
Lipid peroxidation (LPO) status in RBC is indicated in table 6 
(p<0.001). In diabetic control rat, in packed RBC was noted as 
significantly elevated compared to the normal controls. Following 
HC treatment LPO status in rat blood RBCs indicated significant 
reduction compared to respective control groups. 
11]. Streptozotocin induced diabetes 
elevated the rat blood glucose level to greater than 16.0 mmol/dl, 
whereas oral administration of homocastasterone through 15 day 
regimen to diabetic rats diminished the blood glucose level to 9.55 m 
Athithan et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 7, 125-128 
127 
mol/dl, returning the circulating glucose level to within the reported 
range. Use of ethanol in rat is known to depress hematopoiesis and 
contribute significantly to changes in RBC, Platelet and Hb count, 
PCV, MCV, and MCH. Ethanol was however used in this study as a 
vehicle for oral administration of HC to the experimental rat. 
Diabetes is known to cause anemia in humans and reduced RBC 
count in diabetic rat has been reported [12].  
In our study, elevation in RBC count in the normal rat blood post HC 
administration was only 2.5% whereas 20% decrease in RBC count 
was noted in HC administered diabetic rat blood. The observed 
increase in RBC may be due to: (1) RBC generation to compensate 
low tissue oxygen level caused by deficient heart or lung function, 
(2) erythropoietin synthesis and release causing marrow induction 
of red blood cell production, and (3) change in blood plasma volume 
through sodium and water depletion resulting in higher RBC count. 
Increase in red blood cell count can also be due to the anabolic 
steroid potency associated with this ketosteroid similar to that 
noted for 28-homobrassinolide reported [3, 4] earlier from this 
laboratory. Whether the observed decrease in RBC number is due to 
increase in vivo hemolysis or greater spleenic clearance of this cell 
type is not clear however. 
 
Table 4: Effect of homocastasterone on RBC indices 
Group 
 
HCT % MCV fL MCH% MCHC% 
5 Day 10Day 15 Day 5 Day  10Day 15 Day  5 Day  10 Day 15 Day  5 Day 10 Day 15 Day 
Control 44.8±3.04 46.0±3.04 47±3.04 61±7.53 60.2±7.53 60.1±7.53 20.9±2.86 21.3±2.86 21.4±2.86 34.3±2.35 35.4±2.35 35.7±2.35 
Control+HC 43.7±3.09 47.7±3.09 46.7±3.09 61±6.38 59.8±6.38 59.6±6.38 20.5±4.35 20.5±4.35 20.2±4.35 33.6±2.48 34.3±2.48 34.0±2.48 
Diabetic 
control 
50.6±2.38 37.7±2.38 37.4±2.38 63.5±4.84 66.3±4.84 58.1±4.84 21.5±3.15 24±3.15 21.2±3.15 33.9±1.38 36.3±1.38 36.6±1.38 
Diabetic+HC 47.7±2.47* 24.4±2.47* 38.9±2.47 56.9±5.92* 54.8±5.92* 62.1±5.92 19.7±3.45 18.6±3.45 20.0±3.45 34.3±1.94 34.0±1.94 32.3±1.94 
Values are expressed±SD. Group n = 6, #
Group 
 
Indicates statistical significance against normal control (p<0.05), *Indicates statistical significance against 
diabetic control (p<0.05).  
Table 5: Effect of homocastasterone on Platelet indices 
MPV % PDW % PCT fL 











































































Values are expressed±SD. Group n = 6, #
Group 
Indicates statistical significance against normal control (p<0.05), *Indicates statistical significance against 
diabetic control (p<0.05).  
Table 6: Effect of homocastasterone on RBC peroxidation status 
RBC MDA nmmol/mg protein/min 
Control 0.166±0.03 
Control+HC 0.170±0.05 
Diabetic control 1.024±0.07 
Diabetic+HC 0.820±0.04* 
Values are expressed±SD. Group n = 6, #
 
Indicates statistical significance against normal control (p<0.05), *Indicates statistical significance against 
diabetic control (p<0.001).  
The raise in hemoglobin level in the range 0.16–5.66% noted for the 
diabetic rat through the 15 day period of HC administration 
correlates with reported values in humans and could be used as a 
predictive biomarker for reduced mortality of these animals. It can 
be a Prognostic [13] for effective decongestion and possibly weight 
loss in these species.  
In case of normal rats, the increase in Hb content was not in excess 
of 2%, although RBC count reduced by 20%, suggestive of the 
insignificant effect of homocastasterone on rat blood Hb level. The 
hematocrit value of 44-47% noted for control rat through the 15 day 
study did not change effectively following HC administration. For the 
diabetic control however, nearly 26% decline in the hematocrit 
value was noted by day 15, while 18.4% decline only was observed 
following HC fed through the same period. The diabetic control 
hematocrit was nearly 13% higher than normal rat hematocrit at 
day 5. MCV is a measure of the morphological status of RBC and is 
predictive of microcytic, normocytic and macrocytic RB cell 
population in circulating blood. Control rat MCV was without 
significant change through the experimental period. Diabetic control 
MCV decreased 8.5% during the 15 day test period. HC fed diabetic 
rat registered MCV value 10% below diabetic control at day 5 and 
7% above diabetic control at day 15. Where MCV value was high, 
pernicious anemia, alcoholism, vitamin B12/Folic acid deficiency and 
macrocytic anemia is indicated for man. With low MCV, microcytic, 
thalassemia sidero blastic, chronic and iron deficiency anemia are 
suggested. Whether the indicated changes in rat blood MCV due to 
HC is indicative of anemia in the experimental rat is to be 
established. Estimate of Mean Corpuscular Hemoglobin (MCH) and 
Mean Corpuscular Hemoglobin Concentration (MCHC) did not yield 
meaningful differences between normal and diabetic, control and 
treated rats. In rat and mice, the normal WBC counts are reported to 
be in the range 2000–10,000/µl. Changes in white blood cell count is 
known to facilitate diagnosis of bacterial/viral or fungal infections, 
inflammatory disorders such as rheumatoid arthritis, vasculitis, 
inflammatory bowel disease, allergic reactions/asthma and 
leukemia or myeloproliferative neoplasms in humans. In the present 
study, WBC count varied between 25400–26,300/µl for the normal 
rat through 5-15 days. In the diabetic rat, the WBC count was in the 
range 16,400-20,800/µl for the same duration. Oral administration 
of HC diminished the WBC counts 15-39% in the normal rat, 
whereas in diabetic rat an initial reduction in WBC count by 20% at 
day 5 was followed with an increase of 27% in these cell count by 
day 10. However, by day 15, reduction in WBC cell count was noted 
to be 64% in normal and 76% in diabetic rat following HC 
consumption [13].  
Physiological responses as a consequence to WBC count variation in 
the murine species remain to be clearly understood. It is reported 
that sampling site and intrinsic variability due to factors affecting 
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the rodent can cause wide variations in WBC count in rat. Collection 
of blood from the rat tail vein initially and from the heart later 
(day15) during this study, can be considered a possible reason for 
the observed differences noted. The observed increase in rat WBC 
count as opposed to the normal reported range can be a result of 
stress influences experienced by the caged animal. Differential 
counts of lymphocytes, monocytes and granulocytes yielded reduced 
cell count for each of these types following HC administration. 
Lymphocyte count diminished up to 35 % in normal rat whereas this 
cell type reduced only by 25% in diabetic rat following HC intake 
through the 15 day duration. Monocytes reduced greater than 50 % 
during the 15 day study while granulocytes reduced > 80 % in 
normal and diabetic rat [14].  
Blood platelet count registered values of 424-334 x 10-3 per µl for the 
normal rat and 268-179 x 10-3
of HC to diabetic rats possibly enhanced their blood platelet profile 
and improved the hemodynamic status in the animal. Reduction in 
platelet count due to HC in the normal rat probably affected the 
hemostasis potential of the animal contributing possibly to the 
acquired clotting disease in the species [
 per µl for the diabetic control. 
Following HC administration, platelet count reduced in the normal 
rat blood by 14-51% whereas in diabetic rat blood, the platelet 
count increased by 12-38 %. Similar to WBCs, variations in platelet 
count are due to many factors affecting the animal. Specific reasons 
cannot therefore be assigned for the observed change in rat platelet 
count. Since platelets affected the hemodynamic status in an animal, 
it may be construed that administration  
15]. 
Platelet indices such as MPV, PDW and PCT measured in normal, 
diabetic control and HC administered rat blood yielded varying 
results. In humans, an inverse relationship between platelet count 
and MPV values had been suggested[16]. In wistar rat, changes in 
MPV, PDW and P-LCR (platelet-larger cell ratio) had been studied 
earlier as a follow-up of di chlorovinyl dimethyl phosphate pesticide 
administration [17]. Although platelet indices had been studied in 
several investigations, clinical correlations supporting their use have 
not found significant approval. In this study, 15 day oral 
administration of HC resulted in significantly reduced MPV, PDW 
and PCT values in the normal control rat. MPV values reduced 3-9%, 
PDW decreased 6-16% and PCT decreased 16-35% post HC intake 
during the study period. In the diabetic rat, MPV value decreased 16-
28%, PDW reduced 6-13% whereas PCT increased 10-14% during 
the same period. Decrease in PDW and MPV in rats suggest 
thrombocytopenia due to homocastasterone consumption [18-20]. 
Peroxidative damage in the RBC population evaluated indicated 84% 
greater damage in diabetic control rat cells. Even though 
administered level of homocastasterone reduced peroxidative 
damage in the diabetic rat RBCs by 20%, a 2.5% elevation in 
peroxidation was noted in normal rat RBC following administration 
of an identical level of HC. While peroxidative damage remains a 
focal theme when considering factors causing cell dysfunction, 
homocastasterone’s potency to reduce peroxidative damage in 
diabetic rat RBC by 20% should outweigh the observed increase of 
2.5% in the normal rat RBC. The specific causes contributing to the 
contrasting observations shall need further investigation [4, 5]. 
CONCLUSION 
The present study confirms that the plant ketosteroid 
homocastasterone, exhibits anti-hyperglycemic effect. When 
administered, this compound improves platelet indices in diabetic 
rat blood and increased RBC, Hb and WBC levels significantly. 
Peroxidative damage to lipids studied using packed red blood cells 
showed that HC prevented lipid peroxidation in treated rat. The 
molecular mechanism underlying alteration in blood cells and its 
indices requires further study. 
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